



**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

1579-548

09/775,805

**APPLICANT**

HAYNES et al

**FLING DATE**

## GROUP

February 5, 2001

1648

(Use several sheets if necessary)

RECEIVED

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

---

**ABSTRACT**

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
WO 95/29700	11/1995	PCT				
WO 97/14436	4/1997	PCT				
WO 93/15750	8/1993	PCT				
WO 02/024149	3/2002	PCT				

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

\*Examiner

---

**Date Considered**

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

---

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE  
CITATION

(Use several sheets if necessary)

1579-548

Applicant

HAYNES et al

Filing Date

Group

February 5, 2001

1648

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

TRANSLATION

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Sheppard et al, "The characterization of non-progressors: long-term HIV-1 infection will stable CD4+ T-cell levels", AIDS 7:1159-1166 (1993)
	Phair, John P., Keynote Address: "Variations in the Natural History of HIV Infection", AIDS Research and Human Retroviruses 10(8):883-885 (1994)
	Pantaleo et al, "Studies in Subjects with Long-Term Nonprogressive Human Immunodeficiency Virus Infection", N. Engl. J. Med. 332(4):209-216 (1995)
	Cao et al, "Virologic and Immunologic Characterization of Long-Term Survivors of Human Immunodeficiency Virus Type 1 Infection", N. Engl. J. Med. 332(4):201-208 (1995)
	Pantaleo et al, "Major expansion of CD8+ T cells with a predominant V $\beta$ usage during the primary immune response to HIV", Nature 397:463-467 (1994)
	Mellors et al, "Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion", Ann. Intern. Med. 122:573-579 (1995)
	Jurriaans et al, "The Natural History of HIV-1 Infection: Virus Load and Virus Phenotype Independent Determinants of Clinical Course?", Virology 204:223-233 (1994)
	Borrow et al, "Virus-Specific CD8+ Cytotoxic T-Lymphocyte Activity Associated with Control of Viremia in Primary Human Immunodeficiency Virus Type 1 Infection", Journal of Virology 68(9):6103-6110 (1994)
	Haynes et al, "Toward an Understanding of the Correlates of Protective Immunity to HIV Infection", Science 271:324-328 (1996)
	Haynes, Barton F., "Scientific and Social Issues of Human Immunodeficiency Virus Vaccine Development", Science 260:1279-1286 (1993)
	Nowak et al, "Antigenic oscillations and shifting Immunodominance in HIV-1 Infections", Nature 375:606-611 (1995)
	Walker et al, "CD8+ Lymphocytes Can Control HIV Infection in Vitro by Suppressing Virus Replication", Science 234:1563-1566 (1986)
	Baler et al, "HIV suppression by interleukin-16", Nature 378:563 (1995)
	Cocchi et al, "Identification of RANTES, MIP-1 $\alpha$ , and MIP-1 $\beta$ as the Major HIV-Suppressive Factors Produced by CD8+ T Cells", Science 270:1811-1815 (1995)
	Feng et al, "HIV-1 Entry Cofactor" Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor", Science 272:872-877 (1996)
	Wei et al, "Viral dynamics in human immunodeficiency virus type 1 infection", 373:117-122 (1995)
	Palker et al, "Polyvalent Human Immunodeficiency Virus Synthetic Immunogen Comprised of Envelope gp120 T Helper Cell Sites and B Cell Neutralization Epitopes", The Journal of Immunology 142:3612-3619 (1989)
	Berzofsky, Jay A., "Development of artificial vaccines against HIV using defined epitopes", The FASEB Journal 5:2412-2418 (1991)
	Haynes et al, "HIV Type 1 V3 Region Primer-Induced Antibody Suppression Is Overcome by Administration of C4-V3 Peptides as a Polyvalent Immunogen", AIDS Research and Human Retroviruses 11(2):211-221 (1995)

\*Examiner

*Jeffrey Shucker*7/28/03  
Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

## **INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

City. Docket No.

Sec. 1 No.

1579-548

05,775,805

**Applicant**

09/775,805

HAYNES et al

## Group

February 5, 2001

1648

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL DOCUMENT NUMBER DATE NAME CLASS SUBCLASS IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

## TRANSLATION

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
----------	------	---------	-------	----------	-----	----

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

Williams and McAuley, "HLA Class I Variation Controlled for Genetic Admixture in the Gila River Indian Community of Arizona: A Model for the Paleo-Indians". Human Immunology 33:39-46 (1992)	
Hardy, G.H., "Mendelian Proportions in a Mixed Population", Science, N.S. XXVIII,(706):49-50 (1908)	PP?
Schneider et al, "Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara", Nature Medicine 4:397-402 (1998)	
Ferrari et al, "Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers", Proc. Natl. Acad. Sci. USA 94:1396-1401 (1997)	
Cease and Berzofsky, "Toward A Vaccine For AIDS: The Emergence of Immunobiology-Based Vaccine Development", Annu. Rev. Immunol. 12:923-989 (1994)	
Guleria et al, "Auxotrophic vaccines for tuberculosis". Nature Medicine 2(3):334-337 (1996)	
Beddows et al, "Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies". Journal of General Virology 79:77-82 (1998)	
Sullivan et al, "Replicative Function and Neutralization Sensitivity of Envelope Glycoproteins from Primary and T-Cell Line-Passaged Human Immunodeficiency Virus Type 1 Isolates". Journal of Virology 69(7):4413-4422 (1995)	

\*Examiner  7/28/03 Date Considered

E-examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

